WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329504

CAS#: 927961-18-0

Description: Lanifibranor, also known as IVA-337, is a peroxisome proliferator-activated receptors (PPAR) agonist.

Price and Availability

Size Price Shipping out time Quantity
25mg USD 250 2 Weeks
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 1950 2 Weeks
1g USD 3250 2 Weeks
2g USD 4850 2 Weeks
5g USD 8950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-25. Prices are subject to change without notice.

Lanifibranor, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 329504
Name: Lanifibranor
CAS#: 927961-18-0
Chemical Formula: C19H15ClN2O4S2
Exact Mass: 434.0162
Molecular Weight: 434.909
Elemental Analysis: C, 52.47; H, 3.48; Cl, 8.15; N, 6.44; O, 14.71; S, 14.74

Synonym: Lanifibranor; IVA-337; IVA 337; IVA337.

IUPAC/Chemical Name: 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid


InChi Code: InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)

SMILES Code: O=C(O)CCCC(N1S(=O)(C2=CC=C3N=CSC3=C2)=O)=CC4=C1C=CC(Cl)=C4

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F,
Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment
of systemic sclerosis. Expert Rev Clin Immunol. 2016 Dec 12:1-14. [Epub ahead of
print] PubMed PMID: 27899043.